MH
Mauricio Hernandez
Scientist
Scientific training in the United States and Chile. Lead researcher behind the peptide discovery platform and biological validation.
Receptor-first peptide design
Splinter® Peptide Platform
Peptides designed to act exactly where they're needed.
We start from the receptor — the biological lock behind each response — and design the key to fit it. The result: small peptides that are more precise, with fewer unwanted effects, made by chemical synthesis at lower cost and adaptable to different routes of administration. One platform for solutions across human health, animal health, dermatology and personal care.
Precision
Built for the target, not adapted to it.
Efficiency
Small molecules, simpler and more affordable to produce.
Versatility
From topical care to therapies, in people and animals.
Why most peptide programs stall
Great biology, unreachable tissue
Molecule-first
Programs start from a molecule and search for a use. One asset carries all the risk.
Biology-only target selection
Promising biology is often chosen without asking whether a peptide can actually reach it. The problem surfaces late, after capital is spent.
The design engine
Receptor-first, delivery-filtered
One engine, many targets. Each one is triaged on biology and deliverability before design begins.
01
Choose the right target
We focus on the biological targets with the greatest potential for real impact.
02
Design to arrive
Every peptide is designed from the start to reach the place where it has to act.
03
Validate before investing
We confirm the biological effect early, before committing major resources.
Delivery as the second filter
Reaching the target is part of the design
We consider how each peptide will reach its target from day one. That decides where each program is applied, so it advances where it has the best chance to succeed.
Where our peptides make a difference
One platform, three fields of application
The same design engine can be pointed at very different problems — in people and in animals.
Veterinary
Animal health
Bio-specific peptides for production and companion animals.
- Metabolic performance and wellbeing
- Wound healing and tissue repair
- Solutions adapted to each species
Cosmetics
Skin health & dermatology
Topical peptides for skin renewal and protection.
- Skin regeneration and repair
- Protection against oxidative stress and ageing
- High-value ingredients for brands
Bio-specific therapies
Metabolic & regenerative
Targeted therapies designed for a better safety profile.
- Metabolic and liver health
- Preserving muscle during weight loss
- Chronic wound healing and tissue regeneration
Each program advances in the field where it can create the most value, with the right partner.
Proof of chemistry
What the engine produced on its first receptor
We pointed the engine at the growth hormone receptor (GHR) to prove the full workflow, from design to proteomic validation. It demonstrates what the platform can do; it is not our only bet.
Case study: the GHR program
01 · Peptide
Splinter® peptide
02 · Binding
Target receptor
Fat synthesisOFF
Tissue repairON
Selective signalling
Repair without the metabolic cost
Activates regenerative pathways while avoiding the routes linked to metabolic side effects.
- Fewer metabolic side effects
Metabolic arm
Fat synthesis switched off
Reduces the cellular machinery of fat production.
- Hepatic and adipose benefit
Repair arm
Repair machinery switched on
Activates protein synthesis and tissue repair.
- Lean mass preservation
One receptor, two coordinated outputs: a repair arm and a metabolic arm.
Pre-clinical validation supporting the mechanism
673
Significant shifts at 72 h
6.1×
Increase in anabolism
87%
Ribosomal activation
2 labs
Independent confirmation
Key bioactivity and safety assays were performed in two independent laboratories, with concordant direction and magnitude across replicates.
Safety signal
0% cytotoxicity
No cytotoxicity in HeLa lines at concentrations far above physiological levels.
Bioactivity
Proliferation within 72 h
Increased cell proliferation with ECM and collagen pathway enrichment.
Dosing design
Half-life extended >400×
Engineered for weekly administration.
29 candidate peptides screened · assays in two independent laboratories
The team
Scientists, industry leaders and transfer experts
Discovery science, international pharma, and technology transfer — the skills to run an engine, not just a molecule.
FR
Felipe Reyes
Pharmaceutical Industry Expert
Strategic leadership across diverse markets, commercial strategy, market access, value creation and business development.
CP
Cristian Placencia
Senior Pharma Executive
Commercial strategy and leadership across pharmaceutical laboratories in Latin America, driving market growth and regional operations.
JB
Jorge Becar
Legal Lead & IP
Co-founder and legal lead. Edinburgh-trained lawyer with international experience at the United Nations and in public international law.
PP
Patricio Pizarro
Tech Transfer & Strategy
Training in the United Kingdom and Chile. Technology transfer, new ventures and innovation, and Latin American business development.
Platform development
IP and roadmap
Engine
Consolidate the design and screening workflow.
Triage
Prioritise the targets with the highest chance of success.
Programs
Launch first programs in veterinary, cosmetic and therapeutic applications.
Partnering
Ingredient partners and pharma licensing.
GHR case-study patent · PCT/CL2026/050023
Somatotropin Agonist Mimetic Peptides: Compositions and Methods for Tissue Regeneration, Metabolic Modulation and Cytoprotection
Covers the peptide sequences, their compositions and clinical applications. Status: PCT filed · national phase in preparation.
Where partners come in
- Co-develop peptides for cosmetics and dermatology
- License therapeutic and veterinary programs at preclinical stage
- Bring a complementary delivery technology
- Invest in the design engine
Get involved
Point the engine at your problem.
Invest
Back the platform, not a single molecule.
Co-develop
Cosmetic, dermatology and veterinary partners.
License
Therapeutic programs for human and animal health.